Literature DB >> 33608423

Differences in Biomarkers of Inflammation Between Novel Subgroups of Recent-Onset Diabetes.

Christian Herder1,2,3, Haifa Maalmi4,2, Klaus Strassburger2,5, Oana-Patricia Zaharia4,2, Jacqueline M Ratter4,2, Yanislava Karusheva4,2, Mohamed A Elhadad6,7,8, Kálmán Bódis4,2,3, Brenda W C Bongaerts2,5, Wolfgang Rathmann2,5, Sandra Trenkamp4,2, Melanie Waldenberger6,7,8,9, Volker Burkart4,2, Julia Szendroedi4,2,3, Michael Roden4,2,3.   

Abstract

A novel clustering approach identified five subgroups of diabetes with distinct progression trajectories of complications. We hypothesized that these subgroups differ in multiple biomarkers of inflammation. Serum levels of 74 biomarkers of inflammation were measured in 414 individuals with recent adult-onset diabetes from the German Diabetes Study (GDS) allocated to five subgroups based on data-driven cluster analysis. Pairwise differences between subgroups for biomarkers were assessed with generalized linear mixed models before (model 1) and after (model 2) adjustment for the clustering variables. Participants were assigned to five subgroups: severe autoimmune diabetes (21%), severe insulin-deficient diabetes (SIDD) (3%), severe insulin-resistant diabetes (SIRD) (9%), mild obesity-related diabetes (32%), and mild age-related diabetes (35%). In model 1, 23 biomarkers showed one or more pairwise differences between subgroups (Bonferroni-corrected P < 0.0007). Biomarker levels were generally highest in SIRD and lowest in SIDD. All 23 biomarkers correlated with one or more of the clustering variables. In model 2, three biomarkers (CASP-8, EN-RAGE, IL-6) showed at least one pairwise difference between subgroups (e.g., lower CASP8, EN-RAGE, and IL-6 in SIDD vs. all other subgroups, all P < 0.0007). Thus, novel diabetes subgroups show multiple differences in biomarkers of inflammation, underlining a prominent role of inflammatory pathways in particular in SIRD.
© 2021 by the American Diabetes Association.

Entities:  

Year:  2021        PMID: 33608423     DOI: 10.2337/db20-1054

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  8 in total

1.  Clinical variable-based cluster analysis identifies novel subgroups with a distinct genetic signature, lipidomic pattern and cardio-renal risks in Asian patients with recent-onset type 2 diabetes.

Authors:  Jiexun Wang; Jian-Jun Liu; Resham L Gurung; Sylvia Liu; Janus Lee; Yiamunaa M; Keven Ang; Yi Ming Shao; Justin I-Shing Tang; Peter I Benke; Federico Torta; Markus R Wenk; Subramaniam Tavintharan; Wern Ee Tang; Chee Fang Sum; Su Chi Lim
Journal:  Diabetologia       Date:  2022-06-28       Impact factor: 10.460

Review 2.  Islet Inflammation and β Cell Dysfunction in Type 2 Diabetes.

Authors:  Joyceline Cuenco; Elise Dalmas
Journal:  Handb Exp Pharmacol       Date:  2022

3.  Differences in the prevalence of erectile dysfunction between novel subgroups of recent-onset diabetes.

Authors:  Haifa Maalmi; Christian Herder; Gidon J Bönhof; Klaus Strassburger; Oana-Patricia Zaharia; Wolfgang Rathmann; Volker Burkart; Julia Szendroedi; Michael Roden; Dan Ziegler
Journal:  Diabetologia       Date:  2021-11-20       Impact factor: 10.460

4.  The Role of Racial and Ethnic Factors in MicroRNA Expression and Risk for Type 2 Diabetes.

Authors:  Elena Flowers; Alka M Kanaya; Li Zhang; Bradley E Aouizerat
Journal:  Front Genet       Date:  2022-03-18       Impact factor: 4.599

5.  Physical Fitness and Cardiovascular Risk Factors in Novel Diabetes Subgroups.

Authors:  Nina Saatmann; Oana-Patricia Zaharia; Klaus Strassburger; Dominik Hans Pesta; Volker Burkart; Julia Szendroedi; Norbert Gerdes; Malte Kelm; Michael Roden
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

6.  Co‑expressed microRNAs, target genes and pathways related to metabolism, inflammation and endocrine function in individuals at risk for type 2 diabetes.

Authors:  Elena Flowers; Kesava Asam; Isabel Elaine Allen; Alka M Kanaya; Bradley E Aouizerat
Journal:  Mol Med Rep       Date:  2022-03-04       Impact factor: 3.423

Review 7.  S100 Proteins in Fatty Liver Disease and Hepatocellular Carcinoma.

Authors:  Etienne Delangre; Ezia Oppliger; Serkan Berkcan; Monika Gjorgjieva; Marta Correia de Sousa; Michelangelo Foti
Journal:  Int J Mol Sci       Date:  2022-09-20       Impact factor: 6.208

Review 8.  A novel diabetes typology: towards precision diabetology from pathogenesis to treatment.

Authors:  Christian Herder; Michael Roden
Journal:  Diabetologia       Date:  2022-01-04       Impact factor: 10.460

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.